Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIOGEN | 10 | 54 | -0,66 % | ||
| APELLIS PHARMACEUTICALS | 10 | 4 | +1,85 % | ||
| GILEAD SCIENCES | 6 | 5 | +0,81 % | ||
| AXSOME THERAPEUTICS | 6 | 1 | +0,27 % | ||
| ORIC PHARMACEUTICALS | 5 | 2 | +0,77 % | ||
| BIONTECH | 4 | 13 | -1,29 % | ||
| ARDELYX | 4 | 8 | +1,52 % | ||
| ARCELLX | 4 | 2 | 0,00 % | ||
| IMMUNOVANT | 4 | 1 | 0,00 % | ||
| VERTEX PHARMACEUTICALS | 3 | 5 | +0,52 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:12 | Pharvaris reports Q4 results | 1 | Seeking Alpha | ||
| 13:06 | Adagene Inc.: Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) | 8 | GlobeNewswire (Europe) | Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical... ► Artikel lesen | |
| 13:00 | Immunovant falls on late-stage trial setback for TED therapy | 1 | Seeking Alpha | ||
| 12:54 | Pharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 10 | GlobeNewswire (Europe) | Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of deucrictibant... ► Artikel lesen | |
| 12:18 | Citizens reiterates Incyte stock rating on pipeline progress | 3 | Investing.com | ||
| 12:10 | Fortschritte in der Pipeline: Citizens bestätigt Einstufung für Incyte-Aktie | 3 | Investing.com Deutsch | ||
| 12:06 | Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry | 1 | Benzinga.com | ||
| 12:01 | Roivant Sciences Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 11:51 | Pharvaris N.V. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 11:50 | Pharvaris N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11:22 | Rückschlag für Immunovant: Batoclimab verfehlt primären Endpunkt in Phase-3-Studien | 1 | Investing.com Deutsch | ||
| 11:18 | Immunovant's batoclimab fails Phase 3 thyroid eye disease trials | 1 | Investing.com | ||
| 11:06 | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | 9 | GlobeNewswire (Europe) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| 11:06 | Roivant Sciences: Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | 6 | GlobeNewswire (USA) | ||
| 11:06 | Roivant Sciences: Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) | 7 | GlobeNewswire (Europe) | Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no... ► Artikel lesen | |
| 10:10 | Biogen-Übernahme: Roth/MKM stuft Apellis-Aktie auf "Neutral" herab | 3 | Investing.com Deutsch | ||
| 10:10 | Roth/MKM stuft Apellis-Aktie wegen Biogen-Übernahme herab | 2 | Investing.com Deutsch | ||
| 10:06 | Roth/MKM downgrades Apellis stock rating on Biogen acquisition | 2 | Investing.com | ||
| 09:47 | Zai Lab Enters Global Collaboration with Amgen to Explore Novel ADC and BiTE Combination Therapy | 5 | AASTOCKS | ||
| 09:14 | Pfizer and BioNTech halt U.S. COVID-19 vaccine study after recruitment struggles | 48 | Japan Times |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.